Lilly CEO: Affordable Generics And IP Support 'Not Incompatible Ideas'

Lilly’s CEO indicates that the long-standing IPR debate that has generally divided the developed and developing world is largely a “false narrative.” The executive also called for lowering regulatory barriers in India amid expectations of the potential debut of Zepbound/Mounjaro in the country next year.

Eli Lilly CEO David Ricks • Source: BioAsia

Tirzepatide may be on course to India but Eli Lilly and Company’s CEO, David Ricks, made clear that the enabling intellectual property rights (IPR) environment in the country isn't quite optimal. 

The Lilly veteran referred to India’s “special moment” in the world amid geopolitical tailwinds but stressed that the country will...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from India

More from Asia